Literature DB >> 3958371

Flecainide and amiodarone interaction.

P Shea, R Lal, S S Kim, K Schechtman, R Ruffy.   

Abstract

Oral amiodarone therapy was given to seven patients already taking oral flecainide regularly. In one additional patient, administration of flecainide was temporarily discontinued when amiodarone therapy was begun, and then resumed. Amiodarone produced a rise in mean dose-adjusted flecainide plasma level (trough plasma level at steady state/daily dose) from 2.3 +/- 0.8 to 3.4 +/- 0.9 (ng/ml)(mg/day) (p less than 0.01). Accordingly, the mean dose of flecainide required to maintain similar plasma levels of the drug was one-third lower during combined treatment than during therapy with flecainide alone. This drug interaction must be accounted for when amiodarone and flecainide are used concomitantly.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3958371     DOI: 10.1016/s0735-1097(86)80234-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  11 in total

1.  Management of atrial tachycardia in the newborn with enterovirus myocarditis.

Authors:  Daniel H Petroni; Song G Yang; Mudar M Kattash; Christopher S Snyder
Journal:  Ochsner J       Date:  2012

Review 2.  Risk-benefit assessment of amiodarone in the treatment of cardiac arrhythmias.

Authors:  P J Counihan; W J McKenna
Journal:  Drug Saf       Date:  1990 Jul-Aug       Impact factor: 5.606

Review 3.  Recent advances in understanding the pharmacology of amiodarone.

Authors:  S Nattel; M Talajic
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

4.  Altered flecainide disposition in healthy volunteers taking quinine.

Authors:  A Munafo; G Reymond-Michel; J Biollaz
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Pharmacokinetic drug interactions with amiodarone.

Authors:  L J Lesko
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

Review 6.  Adverse effects of amiodarone. Pathogenesis, incidence and management.

Authors:  G V Naccarelli; R L Rinkenberger; A H Dougherty; D M Fitzgerald
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

Review 7.  [Clinical aspects of treatment with amiodarone].

Authors:  W Haverkamp; C Israel; A Parwani
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-09

8.  Combined anti-arrhythmic therapy with class 1 and class 3 drugs.

Authors:  M A James; P Papouchado; J V Jones
Journal:  Postgrad Med J       Date:  1989-08       Impact factor: 2.401

Review 9.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

10.  Effect of amiodarone and desethylamiodarone on the pharmacokinetics of antipyrine in the rat.

Authors:  C K Svensson; L L Liu; P W Knowlton
Journal:  Pharm Res       Date:  1987-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.